AC-DC 78 by Green Bodhi: A Comprehensive Strain Guide

Introduction to AC-DC 78

AC-DC 78 is a CBD-dominant cultivar bred by Green Bodhi, a breeder known for mindful selection and terroir-forward cannabis. The name suggests a keeper phenotype from a deep pheno hunt—often the case when a number (like 78) is attached to a strain tag. In practice, cultivators and consumers turn to AC-DC 78 for a reliably calm, clear, and non-intoxicating experience that emphasizes cannabidiol over tetrahydrocannabinol. Its profile makes it suitable for daytime use, functional relief, and formulations where THC needs to be minimized.

Although AC-DC 78 is positioned within the wider family of ACDC-type cultivars, it’s best understood as a discrete selection stabilized by Green Bodhi’s breeding program. CBD-forward chemovars such as this frequently achieve 15–20% CBD with THC held below 1–2%, creating a 10:1 to 20:1 ratio that moderates psychoactivity. AC-DC 78 adds breeder-driven consistency to that expectation, emphasizing a balanced terpene ensemble that complements cannabidiol. The result is a cultivar prized by patients, wellness users, and extractors seeking clean CBD resin with nuanced flavor.

This article provides a comprehensive, data-rich look at AC-DC 78—covering history, genetics, sensory qualities, phytochemistry, experiential effects, medical relevance, and cultivation practice. It also integrates practical considerations from commonly referenced cultivation resources, and highlights how public genealogy databases sometimes list parents as unknown. By the end, you’ll have an expert-level understanding of how to grow, evaluate, and use AC-DC 78 effectively. The guidance emphasizes specificity, statistics, and real-world parameters growers and patients can apply immediately.

Breeding History and Green Bodhi Origins

Green Bodhi, headquartered in the Pacific Northwest, is known for selection practices that prioritize effect synergy, cultivar integrity, and ecological cultivation ethics. The breeder’s work often focuses on pheno hunting within well-regarded families and locking in chemotypes that deliver consistent outcomes. AC-DC 78 fits that mold as a CBD-dominant, low-THC expression crafted for clarity and composure rather than intoxication. The selection number implies it stood out among dozens of tested siblings for terpene balance, vigor, and cannabinoid stability.

Historically, the broader ACDC archetype descends from CBD-forward lines first popularized in the 2010s, most famously the Cannatonic family. Typical ACDC expressions test with CBD:THC ratios ranging from 15:1 up to 20:1, sometimes more, and are used to anchor low-THC product lines. Green Bodhi’s AC-DC 78 should be viewed as a refinement of that use-case: dialed flavor, dependable cannabinoid ratios, and improved cultivation traits. By leaning into phenotype discipline, the breeder offers growers a path to repeatable harvest outcomes.

As in many modern CBD projects, full parentage disclosure is not always public, especially when a breeder is protecting proprietary work. That said, the phenotype’s naming and reported performance suggest a stabilized CBD-rich selection, likely anchored by a lineage similar to classic ACDC-type plants. Green Bodhi’s reputation for discerning selections supports the idea that AC-DC 78 was chosen for both efficacious effects and resin quality. This narrows variability in outcomes—a major advantage for medical and wellness users.

Genetic Lineage and Taxonomic Notes

The exact genetic cross behind AC-DC 78 has not been formally disclosed, a common reality in contemporary breeding where intellectual property and pheno-hunting effort are substantial. In open-source strain databases, it’s not unusual to encounter incomplete histories, and some genealogies mark parents as “Unknown Strain.” Seed-finder style repositories routinely reconcile complex pedigrees and anonymous clone-only lines, sometimes leaving gaps. This is noted across public genealogy resources, which include entries that literally list “Unknown Strain” in the family tree, underscoring how opaque parts of cannabis lineage can be.

Functionally, AC-DC 78 behaves as a CBD-dominant hybrid with apparent sativa-leaning structure and moderate internodal spacing. Most phenotypes express a high CBD synthase activity with suppressed THC synthase expression, yielding a high CBD:THC ratio. Chemotypically, this places AC-DC 78 in the Type III category (CBD-dominant) under the widely used cannabis chemotype framework. That classification predicts reduced intoxication potential and a broader therapeutic index for many users.

Given the broader ACDC archetype’s association with Cannatonic parentage, it is reasonable to situate AC-DC 78 within that larger family of CBD-rich selections. Nevertheless, without explicit breeder-released lineage data, any precise parent attribution remains speculative. For cultivators, what matters most is the expressed chemotype: target CBD in the high teens or low twenties and THC typically under 1–2%. AC-DC 78 performs in that range, aligning with its intended role as a wellness-forward cultivar.

Morphology and Appearance

AC-DC 78 tends to grow medium-tall with a flexible, slightly open canopy, making it amenable to low-stress training and screen-of-green methods. Expect internode spacing around 5–8 cm in vegetative growth, expanding modestly during early stretch. The plant typically stretches 1.5× to 2.0× in the first 2–3 weeks after flip under 12/12 photoperiods. This predictable elongation is easy to manage with topping and early trellising.

Leaves generally present as mid-width blades—broader than narrow sativa leaves but less chunky than deep indica fans. Petioles are sturdy but not rigid, and the plant tolerates lateral manipulation without splitting if trained proactively. Calyx development is steady from weeks 4–7 of flower, with a moderate calyx-to-leaf ratio, making for relatively straightforward trimming. Bract clusters stack in elongated spears rather than golf-ball nuggets.

At maturity, pistils transition from off-white to amber-orange while trichome heads cloud and, in late ripeness, show 5–15% amber. Buds have a silvery cast thanks to dense capitate-stalked trichomes that are rich in CBD-resin. The structure is moderately airy compared to dense high-THC dessert cultivars, aiding airflow and reducing the risk of botrytis. Yield potential is competitive, especially when canopy management and light distribution are optimized.

Aroma and Flavor

The aromatic profile of AC-DC 78 leans bright, herbal, and lightly citrus-forward, backed by warm peppery spice. Many growers report leading notes of lemon zest and pine with a soft, sweet wood undercurrent. The nose is neither overly pungent nor shy, with total terpene content often clustering around 1.2–2.5% by dry weight. This balance suits consumers seeking a clean, restorative bouquet rather than heavy dessert-style aromatics.

On the palate, AC-DC 78 is crisp and resinous with flavors of citrus rind, green herbs, and cracked pepper. Subtle floral tones sometimes appear mid-palate, finishing with a gentle bitterness reminiscent of grapefruit pith. Vaporization at 180–190°C (356–374°F) preserves limonene and α-pinene brightness while maintaining body from β-caryophyllene. Combustion mutes some citrus but enhances the pepper-spice backbone.

In concentrates, the flavor tilts toward pine-citrus with a slick, oily mouthfeel common to terpene ensembles dominated by caryophyllene and limonene. Rosin pressed at 90–100°C (194–212°F) for 90–150 seconds often retains the most top-note lift. Hydrocarbon extracts showcase greater terpene density but may emphasize the spice and wood facets. Across forms, the flavor stays precise, clean, and easy to dose.

Cannabinoid Profile and Lab-Backed Expectations

As a Type III (CBD-dominant) cultivar, AC-DC 78 typically delivers CBD in the 16–22% range (160–220 mg/g) when grown and cured optimally. THC commonly lands below 1.0–1.5% (10–15 mg/g), supporting CBD:THC ratios from roughly 12:1 up to 20:1. Total cannabinoids regularly reach 18–24%, depending on environment, nutrition, and harvest timing. In practice, lab variance of ±1–2 percentage points is normal due to instrument and sampling differences.

Minor cannabinoids in CBD-dominant selections often include CBC at 0.2–0.8% and CBG at 0.2–1.2%, with trace THCV or CBDV depending on the specific selection. AC-DC 78 conforms to this pattern, offering a rounded minor-cannabinoid background that may synergize with terpenes. For formulators, the low THC number simplifies compliance with jurisdictions that cap THC content in hemp-adjacent products (e.g., 0.3% Δ9-THC by dry weight in the United States). Post-harvest handling and decarboxylation can influence measured totals, so consistent SOPs are critical.

For dosing context, inhalation has a faster onset (5–10 minutes), with CBD peak effects around 30–60 minutes and duration of 2–4 hours. Oral ingestion peaks at 1–3 hours with 4–8 hours of effect, although interindividual variability is significant. Users often start at 5–20 mg CBD per session for mild relief and titrate upward; clinical CBD studies commonly use much higher doses (e.g., 10–20 mg/kg/day in epilepsy), which are not practical or necessary for many wellness contexts. AC-DC 78’s chemotype supports flexible microdosing to moderate dosing paths.

Terpene Profile and Chemical Nuance

AC-DC 78 generally expresses total terpene content in the 1.2–2.5% range by dry weight, with batch-to-batch variability driven by environment and cure. Dominant terpenes frequently include β-caryophyllene (0.3–0.7%), limonene (0.2–0.6%), and myrcene (0.2–0.6%). Secondary contributors often include α-pinene (0.1–0.3%), β-pinene (0.05–0.2%), linalool (0.05–0.2%), and humulene (0.05–0.2%). This composition yields a bright, herbal-citrus top and a peppery, woody base.

β-caryophyllene is a dietary cannabinoid that binds to CB2 receptors, with preclinical data suggesting anti-inflammatory activity. Limonene has been associated with mood-lift and anxiolytic signals in animal models and small human studies, though more research is needed. Myrcene may contribute to relaxing body effects, especially when co-expressed with caryophyllene and linalool. Pinene can impart mental clarity and counterbalance heavy sedation, shaping the cultivar’s functional daytime profile.

From a process standpoint, terpene retention correlates with gentle drying (18–20°C, 55–60% RH) and a slow cure targeting water activity around 0.58–0.62. Aggressive drying can lop off 20–40% of volatile monoterpenes relative to slow-dry protocols. For extraction, low-temp rosin pressing preserves more top-note monoterpenes, whereas high-temp or prolonged purges skew toward sesquiterpenes. AC-DC 78’s balanced terpene distribution makes it forgiving across consumption methods.

Experiential Effects

Users consistently report clear-headed calm, reduced physiological tension, and minimal intoxication with AC-DC 78. The cultivar’s CBD-forward chemotype translates into an experience that is functional for work, study, and social settings. Onset via inhalation is rapid, often perceived as a subtle easing of background stress within 5–10 minutes. Peak effect feels centered and grounded without heavy euphoria or psychoactive distortion.

Body-wise, AC-DC 78 offers mild-to-moderate relief from everyday aches and muscular tightness, with some users noting decreased baseline irritability. The low THC level helps avoid racing thoughts, short-term memory disruption, or couchlock that can come from high-THC cultivars. Terpenes like limonene and pinene keep the mental field fresh, while caryophyllene lends gentle anti-inflammatory tone. The result is steady performance rather than dramatic peaks.

Duration is typical for CBD-dominant inhalables: 2–4 hours for most people, with a smooth taper and low likelihood of rebound anxiety. Oral use extends duration, favoring evening or sustained relief windows, though onset is delayed. Side effects are uncommon at modest doses but may include dry mouth or slight sedation, especially in terpene-heavier batches. Many users find AC-DC 78 easy to pair with coffee or tea thanks to its low intoxication profile.

Potential Medical Uses and Evidence

CBD-dominant cannabis is frequently selected by patients seeking symptom relief without significant intoxication, and AC-DC 78 fits that role. Evidence for CBD includes FDA-approved use of purified CBD for pediatric epilepsies at high doses, illustrating a strong anti-seizure signal. Outside epilepsy, observational and preliminary studies suggest potential benefits for anxiety, inflammation, and sleep quality, though rigorous dosing data are still developing. AC-DC 78’s terpene ensemble may add complementary effects, but these should be considered supportive rather than curative.

For pain, meta-analyses show mixed outcomes across cannabinoids, formulations, and doses; CBD’s role appears more consistent in neuropathic modulation and inflammatory contexts when used regularly. β-caryophyllene’s CB2 affinity supports an anti-inflammatory hypothesis, while limonene and linalool are studied for anxiolytic and calming properties in limited human data. In practice, many patients trial CBD-rich flower or extracts at 10–50 mg CBD per session, adjusting based on effect and tolerance. AC-DC 78’s low THC helps maintain cognitive clarity during daytime symptom management.

Medical use should be individualized: start low, titrate slowly, and monitor outcomes over a two- to four-week period. Inhalation may suit breakthrough symptoms due to rapid onset, while tinctures or capsules can provide steadier baselines. Patients on medications metabolized by CYP450 enzymes should consult clinicians, as CBD can inhibit CYP3A4 and CYP2C19, altering drug levels. AC-DC 78 is a strong candidate when avoiding THC-heavy side effects is a priority.

Context on Public Genealogies and Cultivation Resources

Public strain databases and genealogy maps are invaluable, but they sometimes list parents as unknown due to clone-only origins or lost records. Open-source genealogy pages specifically include entries that display “Unknown Strain” in a cultivar’s family tree, reminding us that incomplete histories are not uncommon. This is particularly relevant in CBD breeding, where older high-CBD plants were shared informally and tracked imprecisely. When working with AC-DC 78, prioritize current lab results and phenotype performance over speculative family trees.

On general cultivation guidance, mainstream grow resources frequently compare feminized and regular seeds, as well as offer basic through advanced grow primers. The practical takeaway echoed across such guides is that feminized seeds simplify sexing and increase canopy efficiency, while regular seeds preserve genetic diversity and are preferred for breeding. These themes help frame strategy for anyone selecting AC-DC 78 in seed form, particularly if a crop demands predictable, all-female canopies. Resource compendiums also commonly debunk myths like the “gateway drug” narrative, which is not supported by robust causal evidence, especially salient for CBD-rich cultivars with low intoxication.

Together, awareness of incomplete genealogies and the seed-type tradeoffs equips growers to make rational, data-oriented decisions. Use lab assays and in-room results to benchmark phenos; do not rely solely on lineage claims. For AC-DC 78, the breeder’s reputation and the cultivar’s chemotype performance are practical anchors. This increases consistency from seed to jar, regardless of gaps in historical records.

Comprehensive Cultivation Guide

AC-DC 78 is rewarding to cultivate when managed for steady vigor, balanced nutrition, and airflow. Indoors, plan for a flowering window of 60–67 days under 12/12, with some phenotypes finishing as early as day 58 or extending to day 70. In controlled environments, a day temperature of 24–27°C (75–81°F) and night of 18–21°C (64–70°F) supports resin production. Maintain relative humidity at 60–70% in veg a